When a pregnant woman takes an antiepileptic drug to control seizures, the last thing she expects is that the medication will harm her unborn child. Yet for decades, drugs like valproic acid—sold under names such as Depakote and Depakene—have been linked to a startling range of birth defects, including spina bifida, cleft palate, heart malformations, and cognitive developmental delays. This is not a fringe concern or a rare, one-off side effect. Studies show that up to 10% of children born to women taking valproic acid during the first trimester have major malformations, compared with 2% to 3% in the general population. That kind of statistical gap is what turns a medical tragedy into a legal liability case.
The central legal question in these lawsuits is simple: Who is responsible when a drug causes devastating harm that could have been avoided or warned against? In the United States, pharmaceutical companies have a duty to warn doctors and patients about known risks. That duty is not passive. A manufacturer cannot bury a risk in the fine print of a 50-page package insert and call it a day. The warning must be clear, prominent, and updated as new evidence emerges. The core failure in many antiepileptic birth defect cases is not that the manufacturer had zero knowledge of the dangers. It is that the manufacturer knew—or should have known—about the teratogenic effects for years and failed to act with appropriate urgency.
Consider the timeline. Depakote was approved for epilepsy in the 1980s. By the early 2000s, multiple peer-reviewed studies had documented a two to three times higher rate of neural tube defects in exposed pregnancies. The FDA eventually required a black box warning—the strongest warning level for prescription drugs—in 2009. But the lawsuits allege that the company delayed, downplayed, and even obscured the data, focusing on minor side effects while giving the serious risks short shrift. In 2011, a federal jury awarded $38 million to a family whose child was born with spina bifida after the mother took Depakote. That verdict was later reduced, but it opened the floodgates. By 2020, the manufacturer had paid over $1.5 billion to settle more than 1,000 birth defect claims.
But winning a pharmaceutical toxic reaction case is not automatic. The plaintiff must prove more than just correlation. The legal standard requires causation: that the drug actually caused the specific injury in this specific case. This is where experts matter. Teratology—the study of birth defects—is a specialized field, and lawyers on both sides hire medical experts to testify about the biological mechanisms, dosage levels, and other risk factors. A woman who took valproic acid while also using alcohol or smoking cigarettes may face a tougher road, because those other exposures can independently cause birth defects. The defense will argue that the harm came from something else, not their drug. Strong plaintiffs’ cases rely on evidence that the defect pattern matches the drug’s known signature and that the timing of exposure aligns with the critical window of fetal development.
Another major hurdle is the “learned intermediary” doctrine. In most states, a pharmaceutical company’s duty to warn runs to the doctor, not directly to the patient. The logic is that the physician is the learned intermediary who weighs risks and benefits and makes the final prescribing decision. If the doctor was adequately warned and still prescribed the drug, the manufacturer may be off the hook. This rule has eroded in recent decades due to direct-to-consumer advertising. When a company runs TV commercials telling pregnant women that a seizure drug is well-tolerated and safe for daily use, it cannot then hide behind the doctor’s knowledge. Courts have recognized that marketing to patients undercuts the intermediary rationale. Still, in cases where the warning label was technically accurate, even if not emphasized enough, defense attorneys will fight hard to shift blame onto the prescribing physician.
The practical reality for families is that these lawsuits are not quick or cheap. They require reviewing decades of internal company memos, FDA submission documents, and medical literature. They hinge on emails that reveal whether executives intentionally minimized risks to protect sales. That is why many cases eventually settle rather than go to trial. A settlement may provide money for lifelong medical care, special education, and lost wages, but it cannot undo the physical damage. And unlike a car crash or a slip-and-fall, the harm in a pharmaceutical toxic reaction case is often invisible at first—a child born healthy may later show seizures, learning disabilities, or behavioral problems that only surface years down the road. This delayed manifestation complicates both medical diagnosis and legal strategy, because statutes of limitations can run out before the full extent of the injury is understood.
What does this mean for the average person? If you or a loved one took an antiepileptic drug during pregnancy and your child was born with a defect, the law does not demand that you prove the drug company was malicious. You must show that the warning was inadequate, that the risk was knowable at the time, and that the medicine’s use caused the injury. It is a high bar, but not an impossible one. The weight of science is on the side of the injured. The question is whether the legal system will deliver justice as slowly and painfully as the manufacturer delivered its warnings.
